Search

Displaying results 7881 - 7890 of 8517 in total
  1. Drug

    Galiximab

    go.drugbank.com/drugs/DB04901
    Investigational

    Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

  2. Drug

    Teclozan

    go.drugbank.com/drugs/DB13205
    Investigational

    Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

  3. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.

  4. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

  5. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

  6. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da.

  7. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.

  8. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.

  9. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered

  10. Drug

    Amylmetacresol

    go.drugbank.com/drugs/DB13908
    Approved

    Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils [L2575].